All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-MOSPD2 monoclonal antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
The claims in the granted patent cover the use of such anti-MOSPD2 antibody/antibody fragment to treat a wide range of cancers which express MOSPD2, including solid tumors and hematological cancers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ofranergene obadenovec,Nivolumab
Therapeutic Area: Oncology Product Name: VB-111
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
First two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VB-601
Therapeutic Area: Immunology Product Name: VB-601
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
VB-601 is the Company’s lead anti-MOSPD2 antibody for immune-inflammatory indications, for which a briefing package for the pre-IND meeting was submitted in June. Based on the FDA's feedback, VBL plans to advance its IND-enabling activities for VB-601 as planned.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ofranergene obadenovec,Paclitaxel
Therapeutic Area: Oncology Product Name: VB-111
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
Data Safety Monitoring Committee has completed its second, pre-planned interim analysis of OVAL Phase 3 study investigating ofranergene obadenovec in patients with platinum-resistant ovarian cancer, and unanimously recommended that the study continue as planned.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VB-601
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
New data implicating the potential of VBL's proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis (RA) is being presented today at the European League Against Rheumatism (EULAR) 2020 E-Congress.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ofranergene obadenovec,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
DSMC reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. Study to proceed without modification.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VB-601
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
VBL Therapeutics's anti-MOSPD2 antibodies that block monocyte migration without affecting T-cells, were able to recapitulate this effect and profoundly reduced inflammation and tissue damage.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ofranergene obadenovec,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
Following the positive interim analysis in the OVAL study, NanoCarrier, intends to extend the ongoing global Phase 3 OVAL clinical trial in ovarian cancer to patients in Japan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ofranergene obadenovec,Bevacizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
Details:
In the Phase 2 study, patients with rGBM who were primed with VB-111 monotherapy that was continued after progression with the addition of bevacizumab (Avastin®) showed significant survival.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
